The future directions in this domain should involve lead optimization and development of more potent and selective HER4 inhibitors as well as extensive molecular biology research work to conclude whether HER4 inhibition is a potential drug target for cancer treatment or not. This evidence concerns the gene ERBB4 and cancer.